Virtual Reality Exhibit Simulates Cancer Fatigue

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

LOS ANGELES--Visitors to the Exhibitor’s Hall at this year’s ASCO meeting had the opportunity to walk in the shoes of a patient with cancer-related fatigue at Ortho-Biotech’s In My Steps virtual reality experience, developed in cooperation with cancer patients and the Fatigue Coalition.

LOS ANGELES--Visitors to the Exhibitor’s Hall at this year’s ASCO meeting had the opportunity to walk in the shoes of a patient with cancer-related fatigue at Ortho-Biotech’s In My Steps virtual reality experience, developed in cooperation with cancer patients and the Fatigue Coalition.

For this virtual journey, you sit in a special chair outfitted with pedals. A technician fits you with a virtual reality helmet (see Figure) that places you in the simulated house, and in the shoes, of a fatigued cancer patient. Using the pedals to "walk" and a hand-guided pointer to direct your movements, you guide the patient through simple tasks made challenging by the resistant pedals that slow your steps. Just making a cup of tea becomes maddeningly difficult as the kettle whistles, the doorbell rings, and an impatient delivery man leaves before you can reach the door. The experience, of course, cannot simulate the debilitating fatigue that many cancer patients describe. In one survey, 29% said they had difficulty just getting out of bed, and 24% were too tired to eat. It does, however, reveal the frustrations such patients feel.

In My Steps is traveling to cancer centers as part of 1-day fatigue awareness workshops for physicians and nurses. To schedule an event, call 1-800-776-2748.

Recent Videos
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content